CG
ACRS icon

Cutler Group’s Aclaris Therapeutics ACRS Stock Holding History

Cutler Group’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-3,300
Closed -$19K – 5581
2021
Q1 		$19K Buy
+3,300
New +$64.5K ﹤0.01% 3245
2017
Q3 		– Sell
-3,900
Closed -$4K – 5759
2017
Q2 		$4K Hold
3,900
– – ﹤0.01% 4965
2017
Q1 		$17K Buy
+3,900
New +$112K ﹤0.01% 3474

Other funds holding ACRS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

Cutler Group's ACRS Position: Q3 2021 in Review

Cutler Group sold out of Aclaris Therapeutics (ACRS) in Q3 2021, closing a stake of 600 shares — an estimated $10K sold.

Cutler Group first reported a position in ACRS in Q3 2017 and held it in 15 quarters. The position peaked at $73K in Q1 2021. 126 funds tracked by Wall St. Rank hold ACRS as of Q3 2021.

  • Cutler Group reported no remaining Aclaris Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Cutler Group sold 600 Aclaris Therapeutics shares in Q3 2021, an estimated $10K.
  • Cutler Group first reported a position in Aclaris Therapeutics in Q3 2017 and held it in 15 quarters.
  • Cutler Group's Aclaris Therapeutics position peaked at $73K in Q1 2021.
  • 126 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q3 2021.

Based on Cutler Group's 13F filing for Q3 2021, filed 26 Oct 2021.